To learn more on MSI heterogeneity in pancreatic cancer, a cohort of 597 operated pancreatic cancers was screened by IHC for loss of the MMR proteins MLH1, PMS2, MSH2, and/or MSH6 on a tissue microarray (TMA). This evidence concerns the gene PMS2 and pancreatic neoplasm.